Last reviewed · How we verify

JCR Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief

JCR Pharmaceuticals Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
JR-141 or Idursulfase JR-141 or Idursulfase phase 3 Enzyme replacement therapy Iduronate-2-sulfatase Rare genetic disease / Lysosomal storage disorder
JR-141 JR-141 phase 3 Enzyme replacement therapy Arylsulfatase A Rare genetic/lysosomal storage disorders

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Alexion Pharmaceuticals, Inc. · 1 shared drug class
  2. BioMarin Pharmaceutical · 1 shared drug class
  3. Eurofarma Laboratorios S.A. · 1 shared drug class
  4. Genzyme, a Sanofi Company · 1 shared drug class
  5. ISU Abxis Co., Ltd. · 1 shared drug class
  6. Masonic Cancer Center, University of Minnesota · 1 shared drug class
  7. Pfizer Inc. · 1 shared drug class
  8. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for JCR Pharmaceuticals Co., Ltd.:

Cite this brief

Drug Landscape (2026). JCR Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jcr-pharmaceuticals-co-ltd. Accessed 2026-05-16.

Related